A recent case study highlights the challenges in treating immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs) in cancer therapy. A 47-year-old woman with breast cancer and myasthenia gravis experienced severe neuromuscular symptoms during ICI treatment. Despite standard treatments failing, a muscle biopsy led to a targeted therapy with eculizumab, significantly improving her condition. The case underscores the necessity for specific, patient-tailored strategies to address the high mortality risk associated with neuromuscular irAEs and calls for more research in this area.
Reference: Nelke C, Pawlitzki M, Kerkhoff R, et al. Immune Checkpoint Inhibition-Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade. Neurol Neuroimmunol Neuroinflamm. 2023 Oct 26;11(1):e200177. doi: 10.1212/NXI.0000000000200177. PMID: 37884388; PMCID: PMC10602369.
